Bosch’s new, fully automated rapid test for COVID-19 can help medical facilities make fast diagnoses.
The rapid molecular diagnostic test runs on the Vivalytic analysis device from Bosch Healthcare Solutions. “We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible. It will speed up the identification and isolation of infected patients,” says Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH.
Developed in just six weeks, the rapid test can detect a SARS-CoV-2 coronavirus infection in under two and a half hours – measured from the time the sample is taken to the time the result arrives. Another advantage of the rapid test is that it can be performed directly at the point of care. This eliminates the need to transport samples, which takes up valuable time. It also allows infected individuals to be identified and isolated immediately. With the tests currently in use, patients must usually wait one to two days for a result.
Bosch’s rapid test is one of the world’s first fully automated molecular diagnostic tests. What’s more, it allows a single sample to be tested not just for COVID-19 but also for nine other respiratory diseases, including influenza A and B, simultaneously.
Bosch’s rapid COVID-19 test is the result of collaboration between the company’s Bosch Healthcare Solutions subsidiary and the Northern Irish medical technology company Randox Laboratories Ltd.
Bosch develops rapid test for COVID-19 (Photo: Bosch Healthcare)